Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 15/20 | 0.67 |
| ▸ | PTPN2 | P17706 | 6/20 | 0.65 |
| ▸ | PTPRC | P08575 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL2694816 | 0.99 | PTPN1 (0.65) | PTPN1PTPN2PTPRC | |
| SCHEMBL5021030 | 0.88 | PTPN1 (0.54) | PTPN1PTPN2PTPRC | |
| SCHEMBL2698107 | 0.84 | PTPN1 (0.47) | PTPN1PTPN2PTPRC | |
| Ammonia Solution, Strong SCHEMBL2692369 | 0.83 | PTPN1 (0.46) | PTPN1PTPN2PTPRC | |
| SCHEMBL2692839 | 0.81 | PTPN1 (0.47) | PTPN1PTPN2PTPRC | |
| SCHEMBL4413820 | 0.80 | PTPN1 (1.00) | PTPN1PTPN2PTPRC | |
| SCHEMBL2690335 | 0.79 | PTPN1 (1.00) | PTPN1PTPN2PTPRC | |
| SCHEMBL29405870 | 0.79 | PTPN1 (1.00) | PTPN1PTPN2PTPRC | |
| SCHEMBL340568 | 0.79 | PTPN1 (1.00) | PTPN1PTPN2PTPRC | |
| SCHEMBL4412462 | 0.78 | PTPN1 (0.72) | PTPN1PTPN2PTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9334295-B2 | Fused aromatic PTP-1B inhibitors | KANEQ PHARMA INC. (CA) | 2016-05-10 | — | — | US | disclosed |
| US-9334295-B2 | Fused aromatic PTP-1B inhibitors | KANEQ PHARMA INC. (CA) | 2016-05-10 | — | — | US | disclosed |
| US-20150045325-A1 | FUSED AROMATIC PTP-1B INHIBITORS | KANEQ PHARMA INC. (CA) | 2015-02-12 | — | — | US | disclosed |
| US-20150045325-A1 | FUSED AROMATIC PTP-1B INHIBITORS | KANEQ PHARMA INC. (CA) | 2015-02-12 | — | — | US | disclosed |
| US-8927526-B2 | Fused aromatic PTP-1B inhibitors | KANEQ PHARMA INC. (CA) | 2015-01-06 | — | — | US | disclosed |
| US-8927526-B2 | Fused aromatic PTP-1B inhibitors | KANEQ PHARMA INC. (CA) | 2015-01-06 | — | — | US | disclosed |
| US-20130281365-A1 | FUSED AROMATIC PTP-1B INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2013-10-24 | — | — | US | disclosed |
| US-20130281365-A1 | FUSED AROMATIC PTP-1B INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2013-10-24 | — | — | US | disclosed |
| US-8481742-B2 | Fused aromatic PTP-1B inhibitors | KANEQ PHARMA INC. (CA) | 2013-07-09 | — | — | US | disclosed |
| US-8481742-B2 | Fused aromatic PTP-1B inhibitors | KANEQ PHARMA INC. (CA) | 2013-07-09 | — | — | US | disclosed |
| US-8481742-B2 | Fused aromatic PTP-1B inhibitors | KANEQ PHARMA INC. (CA) | 2013-07-09 | — | — | US | disclosed |
| US-20120178679-A1 | FUSED AROMATIC PTP-IB INHIBITORS | KANEQ PHARMA INC. (CA) | 2012-07-12 | — | — | US | disclosed |
| US-20120178679-A1 | FUSED AROMATIC PTP-IB INHIBITORS | KANEQ PHARMA INC. (CA) | 2012-07-12 | — | — | US | disclosed |
| US-8168815-B2 | Fused aromatic PTP-1B inhibitors | KANEQ PHARMA INC. (CA) | 2012-05-01 | — | — | US | disclosed |
| US-8168815-B2 | Fused aromatic PTP-1B inhibitors | KANEQ PHARMA INC. (CA) | 2012-05-01 | — | — | US | disclosed |
| US-20100022477-A1 | FUSED AROMATIC PTP-1B INHIBITORS | KANEQ PHARMA INC. (CA) | 2010-01-28 | — | — | US | disclosed |
| EP-2114971-A1 | FUSED AROMATIC PTP-1B INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008089581-A1 | FUSED AROMATIC PTP-1B INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2008-07-31 | — | — | WO | disclosed |
| WO-2008089581-A1 | FUSED AROMATIC PTP-1B INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2008-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178679-A1 | FUSED AROMATIC PTP-IB INHIBITORS | PTPRF, PTPRJ, PTPRCAP | PTPN1 15/4885PTPN2 23/4885PTPRC 7/4885 |
| US-20150045325-A1 | FUSED AROMATIC PTP-1B INHIBITORS | PTPRJ, PTPRF, PTPRCAP | PTPN1 14/4885PTPN2 22/4885PTPRC 8/4885 |
| US-20130281365-A1 | FUSED AROMATIC PTP-1B INHIBITORS | PTPRJ, PTPRF, PTPRCAP | PTPN1 14/4885PTPN2 22/4885PTPRC 8/4885 |
| US-20100022477-A1 | FUSED AROMATIC PTP-1B INHIBITORS | PTPRJ, PTPRF, PTPRCAP | PTPN1 14/4885PTPN2 22/4885PTPRC 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.